Treatment Resistance and Current Advances in Cancer Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 June 2025 | Viewed by 225
Special Issue Editors
Interests: cell signaling and signal transduction; cell cycle and growth; cancer therapy; naturally occurring molecules
Special Issues, Collections and Topics in MDPI journals
Interests: molecular mechanisms in cancer systems; target therapy; anticancer compounds; cell death and autophagy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hailed as a breakthrough in cancer treatment, immunotherapy continues to face significant challenges in clinical practice. The first boundary is the lack of accurate biomarkers in predicting the immunotherapy response. Regretfully, the current markers have proven to be largely ineffective in recognizing the proper eligible patient population due to confounding variables related to specimen features, inter-assay variability and scoring systems. Another major issue is the development of resistance mechanisms, which prevent many patients from receiving benefits from immunotherapy. Depending on whether cancer cells are initially responsive to immunotherapy or not, resistance is technically categorized as primary, adaptive and acquired. Moreover, a new group of side effects, termed as immune-related adverse events (irAEs), further limits the clinical application of immunotherapy.
Considering the current state of the art, we are launching this Special Issue with the aim of gathering the latest advancements, challenges and future directions in cancer immunotherapy. Therefore, we warmly invite and encourage cutting-edge research papers and review articles on topics including checkpoint inhibitors, combination therapies, predictive/prognostic biomarkers, the tumor mutational burden and microsatellite instability. Contributions on resistance mechanisms, personalized medicine, vaccine-based immunotherapy and the microbiome are also highly welcome.
Helen Keller said “Alone we can do so little, together we can do so much”. Nothing could be truer in the fight against cancer!
This Special Issue is supervised by Dr. Silvio Naviglio and Dr. Sapio Luigi and assisted by our Topical Advisory Panel Member Dr. Ragone Angela (University of Campania “L. Vanvitelli”).
Prof. Dr. Silvio Naviglio
Dr. Luigi Sapio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitors
- predictive/prognostic markers
- immunotherapy resistance
- immune-related adverse events
- multiomics analysis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
